ALCAR On Other Exchanges
EN Paris

carmat (ALCAR) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CARMAT (ALCAR)

Related News

No related news articles were found.

carmat (ALCAR) Related Businessweek News

No Related Businessweek News Found

carmat (ALCAR) Details

Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It also develops orthotopic, bioprosthetic, self-regulating, and implantable systems, as well as power supply systems, and control and remote diagnosis systems. The company was founded in 2008 and is based in Vélizy-Villacoublay, France.

81 Employees
Last Reported Date: 03/13/19
Founded in 2008

carmat (ALCAR) Top Compensated Officers

CEO & Director
Total Annual Compensation: €4.8M
Compensation as of Fiscal Year 2018.
CARMAT Announces the Resumption of Production of Prostheses for the Pivotal Study

CARMAT announced the resumption of the production of prostheses for the PIVOTAL study. Following the analysis of information gathered from the experience accumulated with the first cohort of its PIVOTAL study and data recorded on test benches, CARMAT has implemented a number of changes to its manufacturing processes, including the transfer of all production activities to the Bois d’Arcy site, mainly to avoid a risk of malfunctions that could affect the electronic module of the prosthesis. The prostheses that will be used for patients in the second cohort of the PIVOTAL study will come exclusively from the Bois d’Arcy production site where the new procedures are now applied. of the third quarter of 2019, subject to prior approval from both the appropriate authorities in the 3 countries in which the second part of the PIVOTAL study has been authorized so far (Czech Republic, Denmark and Kazakhstan) and the ethical committees of the hospitals that are participating in the study. Once the second cohort (10 patients) has been completed, CARMAT will submit its clinical dossier to the DEKRA certification body with a view to obtain CE marking in 2020.

Carmat SA Presents at ESN European Conference, Apr-05-2019

Carmat SA Presents at ESN European Conference, Apr-05-2019 . Venue: Palais Brongniart, 16 Place de la Bourse, 75002, Paris, France.

CARMAT Reports Earnings Results for the Year Ended December 31, 2018

CARMAT reported earnings results for the year ended December 31, 2018. For the year, the company reported total operating income of EUR 722,000 against EUR 28,000 a year ago. Operating loss was EUR 42,766,000 against EUR 31,035,000 a year ago. Net loss was EUR 41,729,000 against EUR 29,228,000 a year ago.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ALCAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALCAR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALCAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12,942.2x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10,893.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CARMAT, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at